Accutar Biotechnology Announces FDA Clearance of IND Application for Phase I Trial of AC0176 in Prostate Cancer

Accutar Biotechnology, Inc. announced that the US FDA has cleared the company’s investigational new drug application (IND) for AC0176 for the treatment of patients with metastatic CRPC.